Dendritic Cell Vaccination Improves Survival in Advanced Melanoma Patients
Author Information
Author(s): Ridolfi Ruggero, Petrini Massimiliano, Fiammenghi Laura, Stefanelli Monica, Ridolfi Laura, Ballardini Michela, Migliori Giuseppe, Riccobon Angela
Primary Institution: Morgagni-Pierantoni Hospital
Hypothesis
Can dendritic cell vaccination improve overall survival in patients with advanced melanoma?
Conclusion
Dendritic cell vaccination is well tolerated and can lead to longer survival in advanced melanoma patients, particularly when using mature dendritic cells.
Supporting Evidence
- 19% of patients showed overall responses to the treatment.
- 30.7% response rate was observed in patients treated with mature dendritic cells.
- Median overall survival was 24 months for DTH-positive patients compared to 5 months for DTH-negative patients.
Takeaway
This study shows that giving special vaccines made from patients' own immune cells can help them live longer when they have advanced skin cancer.
Methodology
Patients were vaccinated with autologous dendritic cells pulsed with tumor antigens and keyhole limpet hemocyanin, followed by interleukin-2 treatment.
Potential Biases
Potential biases may arise from the non-randomized design and the subjective nature of clinical response assessments.
Limitations
The study had a small sample size and was limited to a specific patient population.
Participant Demographics
21 patients, 13 males and 8 females, median age 52 years (range 35-75).
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website